{"studyId":"paad_iatlas_prince_2022","cancerTypeId":"paad","name":"Metastatic Pancreatic Adenocarcinoma (PRINCE Trial, Nat Med. 2022) - iAtlas Harmonized","description":"Whole-exome sequencing and neoantigen landscape analysis of 93 metastatic pancreatic adenocarcinomas and their matched normals from a randomized phase 2 trial evaluating the efficacy of nivolumab and/or sotigalimab with gemcitabine/nab-paclitaxel (chemotherapy) as first-line therapy for metastatic pancreatic cancer. The reprocessing of raw sequencing data is coordinated by <a href=\"https://cri-iatlas.org/\">CRI iAtlas</a>.","publicStudy":true,"pmid":"35662283","citation":"Padron et al. Nat Med. 2022","groups":"","status":1,"importDate":"2026-02-16 13:44:38","allSampleCount":93,"sequencedSampleCount":93,"cnaSampleCount":0,"mrnaRnaSeqSampleCount":93,"mrnaRnaSeqV2SampleCount":0,"mrnaMicroarraySampleCount":0,"miRnaSampleCount":0,"methylationHm27SampleCount":0,"rppaSampleCount":0,"massSpectrometrySampleCount":0,"completeSampleCount":0,"referenceGenome":"hg38","treatmentCount":0,"structuralVariantCount":0,"cancerType":{"id":"paad","name":"Pancreatic Adenocarcinoma","dedicatedColor":"Purple","shortName":"PAAD","parent":"pancreas"},"readPermission":true,"resourceCounts":[]}